兴科蓉医药年报 2023

2023ANNUAL REPORT年報 2Corporate Information4Financial Highlights6Chairman’s Statement9Management Discussion and Analysis27Directors and Senior Management34Report of the Directors51Corporate Governance Report74Independent Auditor’s Report81Consolidated Statement of Profit orLoss and Other Comprehensive Income82Consolidated Statement of Financial Position84Consolidated Statement of Changes in Equity85Consolidated Statement of Cash Flows88Notes to the Consolidated Financial Statements190Definitions Contents Corporate Information BOARD OF DIRECTORSExecutive Directors Mr. Huang Xiangbin(Chairman)Mr. Lei Shifeng(appointed with effect from 29 March 2023)Mr. Huang Zhijian(appointed with effect from 26 March 2024) 20233 2920243 26 Independent Non-executive Directors Mr. Lau Ying KitMr. Liu WenfangMr. Wang QingMr. Bai Zhizhong AUDIT COMMITTEE Mr. Lau Ying Kit(Chairman)Mr. Liu WenfangMr. Wang QingMr. Bai Zhizhong REMUNERATION COMMITTEE Mr. Wang Qing(Chairman)Mr. Liu WenfangMr. Bai ZhizhongMr. Lei Shifeng(appointed with effect from 29 March 2023) 20233 29 NOMINATION COMMITTEE Mr. Huang Xiangbin(Chairman)Mr. Liu WenfangMr. Lau Ying Kit INTERNAL CONTROL AND CORPORATEGOVERNANCE COMMITTEE 20233 29 Mr. Lau Ying Kit(Chairman)Mr. Wang QingMr. Liu WenfangMr. Bai ZhizhongMr. Lei Shifeng(appointed with effect from 29 March 2023) AUTHORISED REPRESENTATIVES 20243 2620243 26 Mr. Huang XiangbinMr. Li Kin Wai(resigned with effect from 26 March 2024)Ms. Peng Yunlu(appointed with effect from 26 March 2024) COMPANY SECRETARIES Ms. Peng YunluMr. Li Kin Wai(resigned with effect from 26 March 2024) REGISTERED OFFICE PO Box 309Ugland HouseGrand Cayman, KY1-1104Cayman Islands PO Box 309Ugland HouseGrand Cayman, KY1-1104Cayman Islands 2 Sinco Pharmaceuticals Holdings LimitedAnnual Report 2023 Corporate Information (Continued) CORPORATE HEADQUARTERS E5-1805, Global CentreNo. 1700, North Section of Tianfu AvenueHigh-Tech Zone, ChengduSichuanPRC 1700E5-1805 PRINCIPAL PLACE OF BUSINESSIN HONG KONG 1112403 Room 2403, Wing On Centre111 Connaught Road CentralHong Kong CAYMAN ISLANDS PRINCIPAL SHAREREGISTRAR AND TRANSFER OFFICE Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman, KY1-1102Cayman Islands Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman, KY1-1102Cayman Islands HONG KONG BRANCH SHARE REGISTRAR 183171712 1716 Computershare Hong Kong Investor Services LimitedShops 1712-1716, 17/F, Hopewell Centre,183 Queen’s Road EastWan ChaiHong Kong HONG KONG LEGAL ADVISERTian Yuan Law Firm LLP AUDITOR CL Partners CPA LimitedCertified Public AccountantsRegistered Public Interest Entity Auditor STOCK CODE ON THE MAIN BOARD OF THESTOCK EXCHANGE OF HONG KONG LIMITED6833 6833 www.sinco-pharm.com COMPANY’S WEBSITEwww.sinco-pharm.com LISTING DATE10 March 2016 20163 10 Financial Highlights •Revenue of the Group increased by 11.8% or RMB268.6 million toRMB2,540.1 million for the Reporting Period (2022: RMB2,271.5million), among which revenue from sales of human albumin solutionincreased by approximately RMB249.8 million, mainly benefited fromthe increase in sales volume. •11.8%268.62,540.120222,271.5249.8 •Gross profit of the Group increased by RMB17.4 million to RMB323.3million for the Reporting Period (2022: RMB305.9 million), while grossprofit margin decreased from 13.5% in 2022 to 12.7% for the ReportingPeriod. The increase in gross profit was mainly due to the increase inthe sales of human albumin and the revenue from the medical beautyservices. •17.4323.32022305.9202213.5%12.7% •Net profit of the Group decreased by 39.0% to RMB42.4 million forthe Reporting Period (2022: RMB69.5 million), primarily due to theincreased administration expense as the Group increased the businessoperation in research and manufacturing of aesthetic medicinesegment and medical beauty segment. •39.0%42.4202269.5 •42.4202269.527.1 •During the Reporting Period, net profit attributable to owners ofthe Company amounted to RMB42.4 million (2022: net profit ofRMB69.5 million), representing a decrease in net profit of RMB27.1million. •0.0220220.03 •Basic and diluted earnings per share amounted to RMB0.02 for theReporting Period (2022: basic and diluted earnings per Share ofRMB0.03). •202312310.392022202212 310.988,000,000202220,000,0002,032,890,585 •The Board resolved to declare a final dividend in respect of the yearended 31 December 2023 of HK$0.39 cents (2022: final dividendin respect of the year ended 31 December 2022 of HK$0.98 cents)per ordinary share, in an aggregate amount of HK$8,000,000 (2022:HK$20,000,000). The dividend has been proposed by the Directorsof the Company and is subject to approval by the shareholders at theforthcoming general meeting. The final dividend has been calculatedby reference to the 2,032,890,585 issued shares outstanding as atthe date of this report. Chairman’s Statement Dear Shareholders, On behalf of the B